Multi-centre, randomized, double-blind, placebo-controlled, phase II study assessing in two sequential cohorts the safety, efficacy and tolerability of a 15 mg BID and a 30 mg BID doses of SER150TBS in well controlled type II diabetic patients with diabetic nephropathy and albuminuria in stable antidiabetic treatment

Trial Profile

Multi-centre, randomized, double-blind, placebo-controlled, phase II study assessing in two sequential cohorts the safety, efficacy and tolerability of a 15 mg BID and a 30 mg BID doses of SER150TBS in well controlled type II diabetic patients with diabetic nephropathy and albuminuria in stable antidiabetic treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jan 2017

At a glance

  • Drugs SER 150 (Primary)
  • Indications Diabetic nephropathies; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Serodus
  • Most Recent Events

    • 25 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 28 Nov 2016 According to a Serodus media release, last patient has been dosed with the last dose in cohort 2 and key results are expected during the first week of 2017.
    • 28 Nov 2016 Status changed from recruiting to active, no longer recruiting, as per a Serodus media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top